Detalles de la búsqueda
1.
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Pharm Res
; 36(7): 93, 2019 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31044267
2.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26655421
3.
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Future Oncol
; 11(1): 51-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-24901734
4.
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma
; 61(13): 3188-3197, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32762271
5.
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 19(11): 715-722.e6, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31447270
6.
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
Leuk Lymphoma
; 59(9): 2075-2084, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29295653
7.
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Cancer Med
; 7(4): 1043-1055, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533000
8.
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
Leukemia
; 34(8): 2271-2275, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32071430
Resultados
1 -
8
de 8
1
Próxima >
>>